Medical Imaging Reagents and Analysis Equipment

Published - Jan 2010| Analyst - Shalini Shahani Dewan| Code - HLC040C
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • Global revenue of the imaging market was worth approximately $21.8 billion in 2008, a figure that further increased to $22.6 billion in 2009. This is projected to reach $29 billion in 2014, at a CAGR of 5.1% between 2009 and 2014.
  • The largest segment X-ray and computed tomography was nearly $9.2 billion in 2008; this further increased to $9.3 billion in 2009, this is projected to reach $11.3 billion in 2014, for a 5-year CAGR of 3.9%.
  • The Second largest segment ultrasound was nearly $5 billion in 2008; this further increased to $5.1 billion in 2009, this is projected to reach $6.1 billion in 2014, for a 5-year CAGR of 3.4%.

INTRODUCTION

STUDY OBJECTIVES

BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for medical imaging. The key objective is to present a comprehensive analysis of the current market and its future direction as an important tool for the diagnosis of various diseases.

This report explores present and future strategies within the imaging market, including reagents, equipment and systems used for imaging. The improvisation of the market, its setbacks and needs are discussed in this report. Comparisons, usage and the advantages and disadvantages of each imaging system are also discussed in this report. 

A detailed analysis of the imaging industry structure has been conducted. This includes both the imaging reagents and the equipment used. Revenues are broken down by region. Sales figures are estimated for the 5 year period from 2009 through 2014. 

Applications for imaging are also discussed separately in the report, with emphasis on its usage in cardiovascular, oncology, gastrointestinal and central nervous system diseases. The report also covers significant patents and their allotment in each category.

REASONS FOR DOING THIS STUDY

Medical imaging has seen major advances in modern medicine.The “compact revolution” is changing the market of imaging systems. R&D spending, along with increasing competition, patent expiries, new technologies, and an international marketplace are sending the market in new directions. Although the industry did see some setbacks in 2008 due to the economic downturn, new advancements and the need for diagnosis through imaging are helping the market to grow. This study looks at many of the systems affected by these factors. 

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each system/ technology in light of new technologies, growing competition, and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in diagnosis through imaging from the point of view of manufacturers and users. Analytical companies, physicians, the pharmaceutical and biopharmaceutical industries, hospitals and research institutes will find this study to be of interest.

SCOPE OF THE STUDY
 
The scope of this study encompasses the imaging, diagnosing and medical markets. BCC analyzes each market and its applications by its need for diagnosis through imaging, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.
METHODOLOGY 
Both primary and secondary research methodologies were used in this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical, chemical, pharmaceutical, and biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends. 
INFORMATION SOURCES
 
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of pharmaceuticals through contract manufacturing and research. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.
 
ABOUT THE AUTHOR 
 
 
Shalini S. Dewan holds a master’s degree in pharmaceutical chemistry. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest. She was awarded a gold medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents of Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs, Implants and Devices; Imaging Reagents; Regulatory Industry; and Dynamic Sera, Media and Reagents Used in Biotechnology.
 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:  
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers 
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Dec-2006| Analyst - Amy Brock| Code - HLC040B

Report Highlights

  • The U.S. market for medical imaging reagents and analysis tools is valued at a little more than $4.9 billion in 2006 and is expected to grow at an average annual growth rate of 11.9% to reach over $8.4 billion in 2011.
  • Imaging reagents currently comprise the largest segment with a value of $2.97 billion in 2006. Medical imaging reagents are expected to increase at an average annual rate of 10.5% to reach $4.9 billion in 2011. The market for imaging reagents is currently led by radiopharmaceuticals for nuclear medicine imaging. The market for these reagents was over $1 billion in 2006 and is expected to grow with an average annual rate of 11.8% to surpass $1.7 billion in 2011. Ultrasound imaging reagents are expected to experience the most significant growth with an average annual rate of 36% to reach $252.8 million in 2011.
  • Within the image analysis market, tools for the analysis of ultrasound images were $190.5 million in 2006 and are expected to grow at an average annual rate of 13.6% to reach $360.6 in 2011.
Published - May-2004| Analyst - Shalini Shahani Dewan| Code - HLC040A

Report Highlights

  • The total U.S. market for imaging reagents was $2.8 billion in 2003 and is expected to grow to $ 3.9 billion by 2008 at an AAGR (average annual growth rate) of 6.9%.
  • While currently the largest market, the x-ray segment appears stagnant, increasing at a very low rate, while the ultrasound market is rising rapidly with many new developments.
  • The MRI reagent market is the prime market for today since a good number of products are available and many more are in the pipeline.
  • Sales of reagents for cardiovascular applications were $770 million in 2003 and are expected to rise at an AAGR of 7.0%.
  • Reagents used in oncology and GIT are rising at AAGRs of 7.0% and 5.1%, respectively.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report